CellCentric has received funding from BrightEdge to further progress the clinical development of its targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional investment from existing lead investor, Morningside Investments Limited.
What is inobrodib?
Inobrodib is a first-in-class small molecule inhibitor that impacts twin regulatory proteins p300 and CBP and thus affects a number of established, yet elusive to treat oncogenes (including Myc, IRF4 and the Androgen Receptor). The orally bioavailable drug is transitioning into Phase II clinical trials in multiple indications; castration resistant prostate cancer (mCRPC), haematological malignancies as well as specifically targeted tumours driven by genomic alterations.
Official comments
Will West, Chief Executive Officer of CellCentric, commented: “We are very pleased to welcome BrightEdge, alongside our cornerstone investor Morningside, as we continue to pioneer targeted cancer treatment through inhibiting p300/CBP. We now know that our drug can be well tolerated and deliver clear signals of efficacy. The task ahead is to build on that, maximising its impact as a monotherapy and in combination with existing standard of care agents, to treat specific cancer types.”
